Results 21 to 30 of about 77,106 (331)
BONE HEALTH AND GROWTH IN SPINAL MUSCULAR ATROPHY TYPE 2 AND 3
İstanbul Tıp Fakültesi Dergisi, 2022 Objective: Spinal muscular atrophy is a lower motor neuron disease, but other parts of the body could be affected. This study compared bone mineral density with bone metabolism and physical growth rates in patients diagnosed with spinal muscular atrophy ...
Osman Kipoğlu +7 more
doaj +1 more source
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy
Annals of Clinical and Translational Neurology, 2022 To provide a greater understanding of the tolerability, safety and clinical outcomes of onasemnogene abeparvovec in real‐world practice, in a broad population of infants with spinal muscular atrophy (SMA).
Arlene M. D'Silva +13 more
semanticscholar +1 more source
Risdiplam in Type 1 Spinal Muscular Atrophy.
New England Journal of Medicine, 2021 BACKGROUND Type 1 spinal muscular atrophy is a rare, progressive neuromuscular disease that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam is an orally administered, small molecule that modifies SMN2 pre-messenger
G. Baranello +16 more
semanticscholar +1 more source
Safety and Tolerability of Strength Training in Spinal and Bulbar Muscular Atrophy: A Case Report
Journal of Rehabilitation Medicine - Clinical Communications, 2022 Objective: Spinal and bulbar muscular atrophy is characterized by slow-progressive muscle weakness, decreased functional performance and falls. Research into the use of exercise in spinal and bulbar muscular atrophy has shown equivocal to negative ...
Vincent Shieh +7 more
doaj +1 more source
JAMA Neurology, 2021 Key Points Question What are the long-term safety and efficacy of onasemnogene abeparvovec in infants with spinal muscular atrophy type 1? Findings In this ongoing, long-term follow-up safety study of 13 infants with symptomatic spinal muscular atrophy ...
J. Mendell +11 more
semanticscholar +1 more source
Lethal Cardiac Complications in a Long-Term Survivor of Spinal Muscular Atrophy Type 1 [PDF]
Kosin Medical Journal, 2019 Spinal muscular atrophy (SMA) is a rare neuromuscular disease characterized by degeneration of the anterior horn cells of the spinal cord and motor nuclei in the lower brainstem, resulting in hypotonia, progressive proximal muscle weakness, paralysis ...
Min-Jung Cho
doaj +1 more source
Нервно-мышечные болезни, 2022 This study presents the structure and population data of spinal muscular atrophy 5q in the Republic of North Ossetia – Alania. The number of newborns for the period 2000–2020 was 195 954, and the prevalence of spinal muscular atrophy 5q among newborns ...
I. S. Tebieva +4 more
doaj +1 more source
Neurological Research and Practice, 2022 Background Major efforts have been made in the last decade to develop and improve therapies for proximal spinal muscular atrophy (SMA). The introduction of Nusinersen/Spinraza™ as an antisense oligonucleotide therapy, Onasemnogene abeparvovec/Zolgensma ...
S. Jablonka, Luisa Hennlein, M. Sendtner
semanticscholar +1 more source
Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
Developmental Medicine & Child Neurology, 2022 To assess the evolution of bulbar function in nusinersen‐treated spinal muscular atrophy type 1 (SMA1).
H. Weststrate +8 more
semanticscholar +1 more source
Mitochondrial Dysfunction in Spinal Muscular Atrophy
International Journal of Molecular Sciences, 2022 Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder caused by recessive mutations in the SMN1 gene, globally affecting ~8–14 newborns per 100,000.
Eleonora Zilio, V. Piano, B. Wirth
semanticscholar +1 more source